secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001453687-24-000100
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian reports positive Phase 2b MG data, Q2 net income $13.8M, $130M PIPE
-----------------------------------------------------------------------------

- Phase 2b trial of Descartes-08 in MG met primary endpoint: 71% (10/14) of treated patients vs 25% (3/12) placebo had ≥5-point MGC improvement at Month 3 (p=0.018).
- Q2 2024 net income of $13.8M ($0.58/share) vs net loss of $11.4M ($2.23/share) in Q2 2023; revenue included $30M milestone from Sobi.
- Completed $130M PIPE financing in July 2024; cash and equivalents $88.9M at June 30, 2024, expected to fund Phase 3 MG trial and early commercial prep.
- Dosed first SLE patient in Phase 2 trial; IND filing for pediatric basket study expected by year-end 2024; Descartes-15 Phase 1 expected H2 2024.
- Appointed Dr. Kemal Malik to board; End-of-Phase 2 FDA meeting expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/0001453687-24-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000100/rnac-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer